



Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference

June 15, 2020

Live Webcast will be on June 22, 2020

SAN DIEGO, June 15, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m. ET) on Monday, June 22, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.



The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, and clinical development programs in multiple therapeutic areas including a gene therapy for Parkinson's disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy, and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on [LinkedIn](#). (*in collaboration with AbbVie)

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-bank-of-america-securities-2020-napa-biopharma-conference-301076985.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. - Navjot Rai (Media), 858-617-7623, media@neurocrine.com, or Todd Tushla (Investors), 858-617-7143, ir@neurocrine.com